지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2014.6
- 수록면
- 65 - 72 (8page)
이용수
초록· 키워드
오류제보하기
Objectives：The objective of this study was to evaluate the treatment duration and adherence of osmotic-controlled release oral delivery system (OROS) methylphenidate for treatment of attention-deficit hyperactivity disorder (ADHD).
Methods：A total of 843 children with ADHD were recruited : 213 children (25.3%) who had previously taken medications for ADHD and 630 drug-naive children (74.7%) were recruited. The dosage was adjusted according to the clinician’s judgment. The primary efficacy endpoint of this study was treatment retention rate, which was estimated at Week 12 and Week 20 using the Kaplan-Meier curve. The Swanson, Nolan and Pelham-IV (SNAP-IV), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement, and the side effect rating scale were measured at every visit. Remission rates were presented based on SNAP-IV and CGI-S, respectively.
Results：The treatment retention rate at 12 weeks and at 20 weeks was 76.2% and 66.8%, respectively. Divided according to 6?8, 9?11, 12?14 and 15?18 years of age, younger children tended to show a statistically higher treatment retention rate (p=.02). Based on SNAP-IV and CGI scores, children with better response to medication showed tendencies of statistically higher treatment retention rate. The most common adverse events included loss of appetite (7.1%) and insomnia (3.3%). There was no serious adverse event related to the treatment, such as death.
Conclusion：The use of OROS methylphenidate for treatment of ADHD was safe and tolerable for children. In this study, lower age and better treatment response showed a statistically significant relationship with higher treatment adherence. Boys showed a trend of high treatment adherence. The treatment adherence at 20 weeks was satisfactory, however, the treatment adherence after 20 weeks showed a sharp decrease. Therefore, treatment persistence for six months after the beginning of ADHD treatment is important. In addition, the positive role of psycho-education for children and parents is necessary for increasing treatment adherence.
Methods：A total of 843 children with ADHD were recruited : 213 children (25.3%) who had previously taken medications for ADHD and 630 drug-naive children (74.7%) were recruited. The dosage was adjusted according to the clinician’s judgment. The primary efficacy endpoint of this study was treatment retention rate, which was estimated at Week 12 and Week 20 using the Kaplan-Meier curve. The Swanson, Nolan and Pelham-IV (SNAP-IV), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement, and the side effect rating scale were measured at every visit. Remission rates were presented based on SNAP-IV and CGI-S, respectively.
Results：The treatment retention rate at 12 weeks and at 20 weeks was 76.2% and 66.8%, respectively. Divided according to 6?8, 9?11, 12?14 and 15?18 years of age, younger children tended to show a statistically higher treatment retention rate (p=.02). Based on SNAP-IV and CGI scores, children with better response to medication showed tendencies of statistically higher treatment retention rate. The most common adverse events included loss of appetite (7.1%) and insomnia (3.3%). There was no serious adverse event related to the treatment, such as death.
Conclusion：The use of OROS methylphenidate for treatment of ADHD was safe and tolerable for children. In this study, lower age and better treatment response showed a statistically significant relationship with higher treatment adherence. Boys showed a trend of high treatment adherence. The treatment adherence at 20 weeks was satisfactory, however, the treatment adherence after 20 weeks showed a sharp decrease. Therefore, treatment persistence for six months after the beginning of ADHD treatment is important. In addition, the positive role of psycho-education for children and parents is necessary for increasing treatment adherence.
목차
서론
방법
결과
고찰
결론
References
참고문헌 (34)
참고문헌 신청
1. [학술지(정기간행물)] - Shaywitz BA / 1997 / Attention-deficit/hyperactivity disorder / Adv Pediatr 44 : 331 ~ 367
2. [학술지(정기간행물)] - 양영희 / 2008 / 서울시 아동을 대상으로 한 주의력결핍과잉행동장애의 선별기준에 대한 연구 / 신경정신의학 47 (3) : 292 ~ 298
3. [학술지(정기간행물)] - 양수진 / 2006 / 주의력 결핍 과잉 행동 장애의 유병률과 관련 인자 : 서울시 학교 정신보건 사업 / 신경정신의학 45 (1) : 69 ~ 76
4. [단행본] - American Psychiatric Association / 2000 / Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR / American Psychiatric Association
5. [학술지(정기간행물)] - Greenhill L. / 1995 / Attention-deficit/hyperactivity disorder: the stimulants / Child Adolesc Psychiatric Clin North Am 4 : 123 ~ 168
2. [학술지(정기간행물)] - 양영희 / 2008 / 서울시 아동을 대상으로 한 주의력결핍과잉행동장애의 선별기준에 대한 연구 / 신경정신의학 47 (3) : 292 ~ 298
3. [학술지(정기간행물)] - 양수진 / 2006 / 주의력 결핍 과잉 행동 장애의 유병률과 관련 인자 : 서울시 학교 정신보건 사업 / 신경정신의학 45 (1) : 69 ~ 76
4. [단행본] - American Psychiatric Association / 2000 / Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR / American Psychiatric Association
5. [학술지(정기간행물)] - Greenhill L. / 1995 / Attention-deficit/hyperactivity disorder: the stimulants / Child Adolesc Psychiatric Clin North Am 4 : 123 ~ 168
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2015-510-002468426